08:07:53 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-03-28 Ordinarie utdelning CESSA 0.00 DKK
2024-03-27 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-12 Kvartalsrapport 2023-Q1
2023-03-24 Ordinarie utdelning CESSA 0.00 DKK
2023-03-23 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-11-04 Extra Bolagsstämma 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-04-19 Kvartalsrapport 2022-Q1
2022-03-18 Ordinarie utdelning CESSA 0.00 DKK
2022-03-17 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-04-19 Kvartalsrapport 2021-Q1
2021-03-29 Ordinarie utdelning CESSA 0.00 DKK
2021-03-26 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriBioteknik
Cessatech är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av smärtstillande nässpray som vidare används för behandling av akuta smärttillstånd hos barn. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och relaterade produkter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Huvudkontoret ligger i Köpenhamn.
2021-12-08 08:00:00

Copenhagen, Denmark, 8 December 2021 - The CEO and members of the Board of Directors of Cessatech A/S ("Cessatech" or the "Company") have exercised all their warrants of series TO 1 that were issued in connection with the Company's IPO of units that took place in November/December 2020. The exercise period runs until and including 16 December 2021. In total 175,518 warrants of series TO 1 have been exercised by the CEO and members of the Board of Directors. Upon full exercise of the warrants of series TO 1, Cessatech will receive DKK 25.2 million before deduction of transaction related costs.

Warrants of series TO 1
In connection with the Company's IPO in November/December 2020, Cessatech issued units (shares and free of charge warrants). In total there are 2,520,000 outstanding warrants of series TO 1. The CEO Jes Trygved and members of the Board of Directors, with Chairman Adam Steensberg have exercised their warrants, in total 175,518 warrants, which equals DKK 1,755,180.

Jes Trygved, CEO.....................................39.891 warrants 

Board members
Adam Steensberg, Chairman....................27.922 warrants 
Charlotte Videbaek (C-ApS)......................42.868 warrants 
Ulla Buhl (Buhl Krone Holding ApS)..........19.946 warrants
Martin Olin.................................................39.891 warrants  
Peter Birk...................................................5.000 warrants 
Flemming S. Jensen..................................n/a* 
* not permitted according to employment contract

The warrants of series TO 1 are traded on Spotlight Stock Market until 14 December 2021 but can be exercised until the last day in the exercise period, 16 December 2021. Thereafter the warrants will be cancelled.

For further information regarding the exercise of warrants, please contact:
Sedermera Fondkommission
Phone: +46 40 - 615 14 10
E-mail: info@sedermera.se
www.sedermera.se
 

Nordic Issuing
Phone: +46 (0)40-632 00 20
E-mail: info@nordic-issuing.se
www.nordic-issuing.se